BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Laser capture microdissection
,
Fenofibrate
,
rs7903146
,
DNMT1
,
Hepatitis
,
Hypothalamus
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
inhibitors angiogenesis
Summary
General Info
Curated Studies
Most Correlated Studies
Response to IL-12 and Type I IFN with or without TCR and CD28 T-lymphocyte stimulation
Glioblastoma tissues of responders or non-responders before and after bevacizumab combined therapy
Renal cell carcinoma 786-O or A-498 cell xenografts of mice treated with sorafenib or sunitinib
Multiple myeloma minimal residual disease plasma cells post VMP+Rd regimen
Rhabdomyosarcoma A-204 cells treated with dasatinib or pazopanib or sunitinib
Explore Curated Studies Results
Literature
Most Relevant Literature
Efficacy and safety of angiogenesis inhibitors in melanoma: a meta-analysis of seven randomized cont…
Angiogenesis inhibitors: mechanism of action and nephrotoxicity].
Discovery of novel PROTACs based on multi-targeted angiogenesis inhibitors.
Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta‑analysis.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Angiogenesis Inhibitors and Hypertension: Clinical Aspects
Study of Apatinib as an Inhibitor of Tumor Angiogenesis
Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors
Efficacy and Safety Analysis of ICIs Plus Angiogenesis Inhibitors for Treatment of Advanced NSCLC in…
Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ